|
9 Companies |
|
7 Products |
|
7 Products |
|
14 Mechanisms of Action |
|
0 Trials |
|
13 News |
|
- | Enrollment change, Trial termination, Metastases: Pulmonary Rehabilitation in Patients With Sarcoidosis (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=36, Terminated, Sponsor: University Hospital, Lille
N=150 --> 36 | Recruiting --> Terminated; Not enough recruitment
- | Trial termination, Stroma: Stromal Gene Expression During Pulmonary Sarcoidosis (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=110, Terminated, Sponsor: Ohio State University
N=150 --> 36 | Recruiting --> Terminated; Not enough recruitment Suspended --> Terminated; Interim analysis
- Trial primary completion date, Metastases: Pulmonary Rehabilitation in Patients With Sarcoidosis (clinicaltrials.gov) - May 14, 2016
P=N/A, N=150, Recruiting, Sponsor: University Hospital, Lille
Suspended --> Terminated; Interim analysis Trial primary completion date: Jun 2017 --> Jun 2018
- atorvastatin / Generic mfg.
Trial completion, Trial primary completion date: Atorvastatin to Treat Pulmonary Sarcoidosis (clinicaltrials.gov) - Dec 10, 2015
P2, N=56, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Dec 2015
- Trial primary completion date, Metastases: Pulmonary Rehabilitation in Patients With Sarcoidosis (clinicaltrials.gov) - Nov 5, 2015
P=N/A, N=150, Recruiting, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2017
- atorvastatin / Generic mfg.
Enrollment closed, Enrollment change: Atorvastatin to Treat Pulmonary Sarcoidosis (clinicaltrials.gov) - Jun 18, 2015
P2, N=56, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Jun 2015 --> Jun 2017 Recruiting --> Active, not recruiting | N=96 --> 56
- atorvastatin / Generic mfg.
Trial primary completion date: Atorvastatin to Treat Pulmonary Sarcoidosis (clinicaltrials.gov) - Apr 15, 2015
P2, N=96, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | N=96 --> 56 Trial primary completion date: Dec 2015 --> Apr 2016
- || hydroxychloroquine / Generic mfg.
New P3 trial: Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). (clinicaltrials.gov) - Jul 25, 2014
P3, N=94, Completed, Sponsor: University of Milano Bicocca
- Cenplacel-L (human placental derived stem cell therapy) / Celularity
P1 data, Trial termination: Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis (clinicaltrials.gov) - Jul 12, 2014
P1b, N=4, Terminated, Sponsor: Celgene Corporation
Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Terminated; Study Terminated by Sponsor
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, IO biomarker: RIPS: Rituximab for Pulmonary Sarcoidosis (clinicaltrials.gov) - Dec 8, 2013
P2, N=10, Completed, Sponsor: University of Cincinnati
Active, not recruiting --> Terminated; Study Terminated by Sponsor Active, not recruiting --> Completed
- Cenplacel-L (human placental derived stem cell therapy) / Celularity
P1 data, Enrollment change: Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis (clinicaltrials.gov) - Sep 27, 2012
P1b, N=4, Active, not recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed N=12 --> 4
- Cenplacel-L (human placental derived stem cell therapy) / Celularity
Enrollment closed, P1 data: Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis (clinicaltrials.gov) - Sep 27, 2012
P1b, N=4, Active, not recruiting, Sponsor: Celgene Corporation
N=12 --> 4 Recruiting --> Active, not recruiting
- |||| Stelara (ustekinumab) / J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis (clinicaltrials.gov) - Sep 16, 2012
P2, N=173, Completed, Sponsor: Centocor, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed